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There is a need for new noninvasive biomarkers (NIBMs) able to assess cholestasis and fibrosis in chronic cholestatic liver diseases
(CCLDs). Tumorigenesis can arise from CCLDs. Therefore, autoantibodies to tumor-associated antigens (TAA) may be early
produced in response to abnormal self-antigen expression caused by cholestatic injury. Vascular endothelial growth factor receptor-
3 (VEGFR-3) has TAA potential since it is involved in cholangiocytes and lymphatic vessels proliferations during CCLDs. This
study aims to detect autoantibodies directed at VEGFR-3 during bile duct ligation- (BDL-) induced cholestatic injury in rat sera
and investigate whether they could be associated with traditional markers of liver damage, cholestasis, and fibrosis. An ELISA was
performed to detect anti-VEGFR-3 autoantibodies in sera of rats with different degree of liver injury and results were correlated
with aminotransferases, total bilirubin, and the relative fibrotic area. Mean absorbances of anti-VEGFR-3 autoantibodies were
significantly increased fromweek one to week five after BDL.The highest correlation was observed with total bilirubin (𝑅2 = 0.8450,
𝑃 = 3.04𝑒 − 12). In conclusion, anti-VEGFR-3 autoantibodies are early produced during BDL-induced cholestatic injury, and they
are closely related to cholestasis, suggesting the potential of anti-VEGFR-3 autoantibodies as NIBMs of cholestasis in CCLDs and
justifying the need for further investigations in patients with CCLD.
1. Introduction
Cholestasis is defined as a decrease in bile flow. It can
arise at the hepatocellular level because of impairment of
bile secretion by hepatocytes or at cholangiocellular level,
generally by obstruction of bile flow through intra- or extra-
hepatic bile ducts by gall stones or local malignancies [1].
Cholestasis is the pivotal hallmark of the so-called chronic
cholestatic liver diseases (CCLDs), but it may also occur in
the advanced stage of other chronic liver diseases (CLDs),
such as alcoholic liver disease, nonalcoholic fatty liver disease,
and chronic hepatitis B and chronic hepatitis C [2]. When
left untreated, cholestasis may drive, in the long term, to
tumorigenesis of cholangiocytes [3], the epithelial cells that
line bile ducts and normally contribute to the modification of
bile volume and composition. This evolution to a malignant
phenotype of cholangiocytes, similar to cholangiocarcinoma,
takes place through a series of functional and structural
changes that affect cholangiocytes, starting early after the
initial cholestatic insult by activation, proliferation, and
secretion of neuroendocrine factors [4]. Chronic cholestatic
liver injury is also accompanied by the development of
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hepatic fibrosis referring to the inappropriate tissue repair
via excessive connective tissue deposition in the liver [5],
which is a common scenario CCLDs share with all CLDs.
Fibrosis is dynamical as it can progress to cirrhosis, a
condition hardly reversible with significant morbidity and
mortality and growing prevalence worldwide [6]. Cholestasis
and fibrosis have enormous economic impact on health
care expenditures which further increase when cirrhosis and
malignant states are reached [7]. Moreover, current screening
methods for cholestasis and fibrosis, especially liver biopsy,
have significant limitations [8], thus justifying the exploration
of new accurate noninvasive biomarkers (NIBMs) able to
early assess cholestasis and fibrosis to estimate the prognosis
and determine the surveillance strategies in CCLDs.
Autoantibodies against tumor-associated antigens (TAA)
represent promising candidates for NIBMs in liver malig-
nancies, such as cholangiocarcinoma [9], and early states
of malignancies, like early chronic cholestatic liver injury.
In some case, the mere presence of autoantibodies to TAA
may precede the clinical diagnosis of liver cancer [10]. This
offers a window of opportunity to intervene and prevent or
redirect the course of the disease. In addition, contrastingly
to polypeptides, antibodies do not undergo proteolysis in
serum, and therefore they are highly stable with half time
in the bloodstream ranging from 7 to 30 days depending on
the subclass of immunoglobulin [11]. In cholangiocarcinoma
patients, autoantibodies directed against p53, heat shock
protein 70, enolase 1, and ribonuclease/angiogenin inhibitor
1 have already been reported [12, 13]. The mechanism that
triggers the autoantibody response against TAA has still not
been elucidated but could be consequent to abnormal self-
antigen expression by tumor cells, through chemical alter-
ation, mutation, posttranslational modification, misfolding,
aberrant cleavage or localization, and overexposure and/or
exposure or spillage of new TAA, in conjunction with
the development of an inflammatory reaction within the
tumormicroenvironment [11, 14].The elicited autoantibodies
oriented to these neoepitopes may be involved in tumor
surveillance and regulation, a process that involves activation
of immunocompetent cells, leading to tumor cell apoptosis
[14]. Nowadays, thanks to the progress in the knowledge of
CCLDs, in part through the development of animal models
like the bile duct ligation (BDL) model of chronic cholestatic
liver injury, new autoantibodies to TAA with potential as
NIBM can be discovered.
Even though to date only autoantibodies to vascular
endothelial growth factor receptor-2 have been reported in
a glioblastoma patient [15], all the proteins from the vascular
endothelial growth factor (VEGF) family are potential TAA
because of their crucial role in tumor growth. Vascular
endothelial growth factor receptor-3 (VEGFR-3), a tyrosine
kinase receptor for VEGF-C andVEGF-D, has been shown to
play a critical role in the pathogenesis of different proliferative
events during CLDs, including that of lymphatic vessels [16,
17] and cholangiocytes [4, 18]. In the latter, the upregulation
of VEGFR-3 and secretion of VEGF-C ligand have appeared
to mediate the adaptive proliferative response of cholan-
giocyte to BDL-induced early cholestatic liver injury via
an autocrine mechanism that involves activation of inositol
1,4,5-triphosphate/[Ca2+]i/protein kinase C alpha and phos-
phorylation of Src/extracellular signal-regulated kinases 1/2
[18]. Similarly, VEGF-D/VEGFR-3 signaling pathway has
been suggested to account for the expansion of the lymphatic
vessel network that occurs according to the degree of liver
fibrosis in CLDs [16, 19]. Based on these facts, the aim of
this work was to explore the production of autoantibodies
to VEGFR-3 in BDL-induced cholestatic liver injury and
investigate whether absorbances associated with the serum
levels of autoantibodies to VEGFR-3 are correlated with
traditional markers of liver damage, cholestasis, and fibrosis.
2. Materials and Methods
2.1. Animals. Thirty-six male Wistar rats (300–400 g) were
included in this study and divided into seven groups. Five
rats were used as a control group without operation. Sixteen
underwent BDL.These animals were sacrificed oneweek later
(𝑛 = 5), three weeks later (𝑛 = 7), and five weeks later (𝑛 = 4).
Fifteen rats underwent sham operation.These animals (𝑛 = 5
per group) were sacrificed at same times as BDL groups.
All rats were housed in plastic cages and maintained in
an environmentally controlled room (22 ± 2∘C, 65 ± 10%
humidity) with a 12-hour light/dark cycle; food and water
were given ad libitum. The Institutional Committee on care
and use of Experimental Animals at the Tecnolo´gico de
Monterrey approved this study with protocol number 2013-
Re-001.
2.2. Bile Duct Ligation. All rats that underwent BDL
and sham operations received intraperitoneal injection of
ketamine at 50mg/kg (Anesket, Pisa Agropecuaria, Hidalgo,
Mexico) and xylazine at 10mg/kg (Sedaject, Vedilab, DF,
Mexico) to induce anesthesia. In BDL groups, a laparotomy
was performed, and the commonbile duct was double-ligated
with 4-0 silk and cut between the ligatures. In rats that
underwent sham operation, common bile duct was isolated
but not ligated, neither cut. Then linea alba and skin were
closed with 4-0 Vicryl and 3-0 Prolene, respectively. All
surgeries were performed under aseptic conditions.
Before sacrificing, rats were anesthetized by ether inhala-
tion (J. T. Baker, Center Valley, PA, USA) and blood samples
were collected by cardiac puncture. Serum was obtained and
stored at −20∘C. Then, animals were immediately sacrificed
by cervical dislocation, and the liver was removed, sectioned,
and fixed in 10% neutral buffered formalin for morphometric
quantification of fibrosis.
2.3. Serum Biomarkers of Liver Injury and Cholestasis. Serum
alanine aminotransferase (ALT), aspartate aminotransferase
(AST), and total bilirubin (TB) were determined spectropho-
tometrically using an automatic biochemical analyzer ILab
Aries (Instrumental Laboratory, Holliston, MA, USA).
2.4. Morphometric Quantification of Fibrosis. Postfixed liver
tissues were embedded in paraffin. Liver slices 4 𝜇m thick
were prepared and stained with picrosirius red stain kit
(Abcam, Cambridge, MA, USA) according to manufacturer’s
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Table 1: Measurements of traditional markers of liver injury and cholestasis in serum and fibrosis in the liver.
Control Sham BDL
(𝑛 = 5) Week 1 (𝑛 = 5) Week 3 (𝑛 = 5) Week 5 (𝑛 = 5) Week 1 (𝑛 = 5) Week 3 (𝑛 = 7) Week 5 (𝑛 = 4)
Liver/body
weight ratio (%) 3.98 ± 0.32 3.87 ± 0.47
b 4.07 ± 0.17b 3.68 ± 0.32b 5.35 ± 0.40a 6.99 ± 1.02ac 6.84 ± 0.65a
AST (U/L) 141.20 ± 13.93 160.20 ± 37.16b 117.40 ± 22.07b 126.20 ± 23.79b 862.83 ± 394.96a 974.71 ± 330.69a 1084 ± 607.64a
ALT (U/L) 71.60 ± 13.05 71.80 ± 14.86b 67.60 ± 13.13b 72.20 ± 18.30b 172.83 ± 69.08a 139.57 ± 49.43a 176.25 ± 81.89a
TB (mg/dL) 0.12 ± 0.05 0.10 ± 00.00b 0.10 ± 00.00b 0.08 ± 0.05b 7.62 ± 2.68a 8.97 ± 1.77a 8.95 ± 2.32a
Relative fibrotic
area (%) 0.4292 ± 0.1239 0.45 ± 0.15
b 0.50 ± 0.05b 0.45 ± 0.11b 0.84 ± 0.19a 8.33 ± 1.20ac 17.17 ± 0.33ac
Data were expressed as mean ± standard deviation. a𝑃 < 0.05 for BDL and sham groups versus control group; b𝑃 < 0.05 for BDL groups versus equivalent
sham groups; and c𝑃 < 0.05 for BDL at week 3 versus BDL at week 1 and BDL at week 5 versus BDL at week 3. ALT: alanine aminotransferase; AST: aspartate
aminotransferase; BDL: bile duct ligation; TB: total bilirubin.
protocol. Collagen content was assessed by morphometric
analysis of picrosirius red-stained liver sections. Thirty pic-
tures per animal were taken at 10x magnification with a
microscope (Olympus BX41 TF, Melville, NY, USA) and
digital camera (Olympus DP20, Melville, NY, USA). Pic-
tures were processed using imaging software (ImageJ 1.49v,
National Institutes of Health, USA). Data were expressed as
relative fibrotic area.
2.5. Indirect Enzyme-Linked Immunosorbent Assay (ELISA).
An indirect ELISA was performed to detect the presence
of VEGFR-3 specific autoantibodies in rat sera from con-
trol, sham, and BDL groups. Plates (Nunc MaxiSorp, San
Diego, CA, USA) were coated with 1.5 𝜇g of VEGFR-3
peptide (LIPPSO, Girona, Spain) diluted in 50mM sodium
carbonate buffer pH 9.6 and incubated overnight at 4∘C.
After blocking overnight at 4∘C with 3% skimmed milk,
plates were incubated 2 h at 30∘C with rat sera diluted in
PBS with 0.05% Tween 20. Then, horseradish peroxidase-
conjugated rabbit anti-rat (Abcam, Cambridge, MA, USA)
diluted 1 : 5000 was added and incubated for 45min at 30∘C.
Horseradish peroxidase activitywas assessed by adding 1-Step
ABTS Substrate Solution (Life Technologies, Waltham, MA,
USA). Optical density of samples was determined at 405 nm
(Tecan Genios Pro, Ma¨nnedorf, Switzerland). Negative and
positive controls were included under the same conditions.
Each sample was tested as duplicates.
2.6. Statistics Analysis. All data represent mean ± standard
deviation. A MANOVA was employed using six dependent
variables (liver/body weight ratio, AST, ALT, TB, absorbance
relative to the serum level of autoantibodies to VEGFR-3,
and relative fibrotic area) with groups corresponding to the
control, the three respective sham and BDL procedures with
endpoints after one, three, and five weeks. A linear model
with fixed effects was adjusted to each dependent variable
using the control group as the intercept. Then, comparisons
between consecutive BDL groups and between BDL and
equivalent sham groupswere performed. Furthermore, linear
regressions were performed with the absorbance relative
to the serum levels of autoantibodies to VEGFR-3 as the
response variable and AST, ALT, TB, and the relative fibrotic
area as regressors. Finally, Benjamin-Hochberg corrections
were employed to control the false discovery rate, which was
defined to be at the 0.05 level. All statistical analyzes were
performed using R package.
3. Results
3.1. Validation of the BDL Animal Model. A panel of tradi-
tional markers of BDL-induced liver injury (AST and ALT),
cholestasis (TB), and fibrosis (relative fibrotic area) was
assessed in order to validate the BDL animal model (Table 1).
As expected, liver/body weight ratio, AST, ALT, TB, and the
relative fibrotic area were all significantly elevated in the three
BDL groups when compared to control group and remained
significantly higher than equivalent sham groups throughout
the experiment. Although a tendency of increment according
to the time of BDL is observed for all the studiedmarkers dur-
ing the five weeks of the experiment, only differences in the
relative fibrotic area between all consecutive groups and in the
liver/bodyweight ratio between the 1st week and the 3rdweek
reached significance. Furthermore, no difference was signifi-
cant between the control and sham groups for all the studied
markers. Therefore, our BDL animal model was validated as
an accurate model of liver injury, cholestasis, and fibrosis.
3.2. Serum Autoantibodies to VEGFR-3 Are Produced during
BDL-Induced Chronic Cholestatic Liver Injury. The analysis
of indirect ELISA showed that, in every BDL group, themean
of absorbances associated with the serum levels of autoanti-
bodies to VEGFR-3 is significantly higher than control and
equivalent sham groups (Figure 1). At the 1st week, the mean
of absorbances increased up to 4 times compared to the
control group (mean value of absorbance at the 1st week
after BDL: 0.5103 ± 0.0814; 𝑃 = 1.69𝑒 − 06). The mean of
absorbances continued to increase at the 3rd week (mean
value of absorbance at the 3rd week: 0.5352 ± 0.0935) and
reached a maximum level at the 5th week (mean value of
absorbance at the 5th week: 0.5864 ± 0.1307) in BDL groups.
Nevertheless, no significant difference between consecutive
BDL groups was reached. Means of absorbances associated
with the serum levels of autoantibodies to VEGFR-3 of sham
groups was not significantly different from that of the control
group.
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Figure 1: Comparative evaluation of the absorbances relative to
the serum levels of autoantibodies to VEGFR-3 by indirect ELISA.
Optical density was measured at 405 nm in control group (white
bar) (𝑛 = 3), BDL groups (black bars) at week 1 (𝑛 = 5), week 3
(𝑛 = 7), and week 5 (𝑛 = 4), and sham groups (grey bars) at week 1
(𝑛 = 3), week 3 (𝑛 = 3), and week 5 (𝑛 = 3). a𝑃 < 0.05 for BDL and
sham groups versus control group; b𝑃 < 0.05 for BDL groups versus
equivalent sham groups. Data were expressed as mean ± standard
deviation. BDL: bile duct ligation.
3.3. Absorbances Associated with the Serum Levels of Autoan-
tibodies to VEGFR-3 Are Correlated to AST, ALT, TB, and
the Relative Fibrotic Area. Correlations between absorbances
associatedwith the serum levels of autoantibodies toVEGFR-
3 from the indirect ELISA and AST (Figure 2(a)), ALT
(Figure 2(b)), TB (Figure 2(c)), and the relative fibrotic area
(Figure 2(d)) were performed. The highest correlation was
observed between absorbances associated with the serum
levels of autoantibodies to VEGFR-3 and TB (𝑅2 = 0.8450,
𝑃 = 3.04𝑒 − 12). Absorbances associated with the serum
levels of autoantibodies to VEGFR-3 also closely correlated
with AST (𝑅2 = 0.5865, 𝑃 = 1.24𝑒 − 06), ALT (𝑅2 = 0.4555,
𝑃 = 4.90𝑒 − 05), and the relative fibrotic area (𝑅2 = 0.4442,
𝑃 = 6.47𝑒 − 05).
4. Discussion
Autoantibodies are not considered anymore as an exclusive
hallmark of autoimmune disorders. In fact, autoantibodies
are abundant and ubiquitous in the serum of all humans
[20]. Using protein microarrays, Nagele et al., 2013, demon-
strated that age, gender, and disease influence autoantibodies
serum level in human and proposed that disease-induced
perturbations in individual autoantibody profiles present an
opportunity to detect accurately and diagnose diseases [20].
In CLDs, autoantibodies have been detected first in autoim-
mune liver diseases, such as primary biliary cirrhosis and
primary sclerosing cholangitis, the clinically most important
CCLDs, and more recently in viral hepatitis, drug-induced
hepatitis, alcoholic liver disease, nonalcoholic fatty liver dis-
ease, hepatocellular carcinoma, and cholangiocarcinoma [21].
Autoantibodies detected in CLDs target a wide repertoire
of host antigens, which include proteins from the nucleus,
the cytoskeleton, liver kidneymicrosomes, themitochondria,
and the cytoplasm of neutrophilic granulocytes, as well as
liver soluble antigens, asialoglycoprotein receptors, TAA,
and stress proteins [21]. However, this list is continuously
growing thanks to the advances in the understanding of
the pathogenesis of CLDs and the improvement of conven-
tional technologies (ELISA, indirect immunofluorescence,
and immunoblotting) for the detection of autoantibodies as
well as the development of new efficient technologies (laser
bead immunoassays, antigen microarrays, and line immu-
noassays), which offer the opportunity to manage a higher
number of samples with lower costs.
In the present study, we focused on autoantibodies
directed against TAA since cholestasis and CCLDs have been
associated with liver and biliary tree malignancies, such as
cholangiocarcinoma and hepatocellular carcinoma. Hepato-
cellular carcinoma may arise in the long term of chronic
cholestatic liver injury. However, this causal relationship
seems unusual as only 1–12% of patients with hepatocellu-
lar carcinoma manifest obstructive jaundice as the initial
complaint [22]. Cholestasis with chronic inflammation has
also been linked to carcinogenesis in cholangiocarcinoma. In
combination, both conditions can promote the four major
cancer phenotypes: (1) autonomous cell proliferation; (2)
invasion/metastases; (3) escape from senescence; and (4)
evasion of cell death [23].Moreover, it has been demonstrated
that malignant cholangiocytes proliferate more rapidly after
BDL, thereby emphasizing the role of obstructive cholestasis
as a potent promotor of intrahepatic cholangiocarcinoma
growth and progression [24]. The mechanism of autoan-
tibody induction against TAA is still an area of debate.
Autoantibodies are probably induced because cells under-
going malignant transformations express self-antigens that
were not evident before [14]. Another explanation is that,
during the earliest stage of tumorigenesis, proteins are likely
mutated, overexpressed, posttranslationally modified, mis-
folded, aberrantly cleaved, or aberrantly localized in tumor
cells [11]. Under these conditions, altered proteins may pass
from an unreactive state to TAA, thus eliciting the production
of autoantibodies to try to control the growth of the TAA-
expressing tumor.
In particular, we focused on VEGFR-3, the specific recep-
tor for VEGF-C and VEGF-D, because (1) it is already known
that VEGF-C/VEGF-D/VEGFR-3 signaling pathway is cru-
cial for the growth and maintenance of tumors, including
cholangiocarcinoma [25, 26] and hepatocellular carcinoma
[27]; (2) VEGFR-3 is involved in cell proliferation during
chronic cholestatic liver injury [18]; (3) VEGFR-3 expression
is altered in response to chronic cholestatic liver injury
[18, 28]; and (4) structural and functional changes occur in
VEGFR-3-expressing cells during chronic cholestatic liver
injury [4, 19]. In response to obstructive cholestatic liver
injury, cholangiocytes evolve according to three interrelated
phenotypes [4]. Early after BDL, an ischemic-reperfusion
phenotype, characterized by cholangiocyte depolarization,
abnormal ion transport, hypometabolism, and hepatocytic
apoptosis, is induced [4].This phenotype, in turn, could trig-
ger the activation of cholangiocytes which start to proliferate
and secrete neuroendrocrine factors to compensate for the
loss of biliary cells and sustain secretory activities [3, 4]. In the
long term, cholestatic injury drives to tumorigenesis, where
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Figure 2: Correlations between absorbances associatedwith the serum levels of autoantibodies toVEGFR-3 and a panel of traditionalmarkers
of liver injury, cholestasis, and fibrosis measured in serum and liver. Correlations between absorbances associated with the serum levels of
VEGFR-3 autoantibody obtained in the indirect ELISA and (a) serum AST activity, (b) serum ALT activity, (c) TB serum levels, and (d)
relative fibrotic area in liver obtained in all experimental groups. ALT: alanine aminotransferase; AST: aspartate aminotransferase; TB: total
bilirubin; VEGFR-3: vascular endothelial growth factor receptor-3.
the tumorous tissue principally consists of cholangiocyte
parenchyma [4]. A study of Gaudio et al. revealed that this
adaptive proliferative response of cholangiocyte to cholestasis
is mainly mediated by the upregulation of VEGFR-3 and
secretion of VEGF-C, through activation of inositol 1,4,5-
triphosphate/[Ca2+]i/protein kinaseC alpha and phosphory-
lation of Src/extracellular signal-regulated kinases 1/2, during
the first week after BDL injury [18]. The increased prolifera-
tion of cholangiocytes in normal rats chronically treated with
recombinant VEGF-C and the decreased cholangiocyte pro-
liferationwhenVEGF is immunoneutralized by antibodies to
VEGF-C sustain this theory [18]. Along with cholangiocyte
proliferation, VEGF-D/VEGFR-3 signaling pathway has also
been implicated in the pathologic reactivation of lymphan-
giogenesis during CLDs [17]. In patients with viral forms of
CLDs, the numbers of lymphatic vessels and their areas are
increased according to the degree of fibrosis [19]. Therefore,
VEGFR-3 may be converted in TAA during the early steps
of the progression of CCLDs towards tumorigenesis. For
that reason, we investigated the production of autoantibodies
to VEGFR-3 in the BDL-model of chronic cholestatic liver
injury.
To determine whether BDL induces a measurable pro-
duction of VEGFR-3 autoantibodies in serum, we performed
an indirect ELISA by coating wells with VEGFR-3 peptide
[29]. We found that absorbances associated with the serum
levels of autoantibodies to VEGFR-3 in BDL groups were
systematically higher than control rats. This result demon-
strates that BDL triggers the serum production of autoan-
tibodies to VEGFR-3, which is consistent with the study of
Thomas et al., 2012, who reported that the lack of lymphatic
drainage, as occurs in the BDL animal model, promotes
autoimmunity [30]. Absorbances associated with the serum
levels of autoantibodies toVEGFR-3 in BDL groups increased
significantly as soon as the 1st week after BDLwhen compared
to control group. This may offer the opportunity of using
autoantibodies to VEGFR-3 to early diagnose BDL-induced
chronic cholestatic liver injury. Moreover, we showed that
these absorbances kept on increasing throughout the five
weeks of the experiment even though no significance was
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reached between consecutive BDL groups, thus suggesting
that autoantibodies to VEGFR-3 could be appropriate to
monitor the progression of BDL-induced chronic cholestatic
liver injury.
Studies on the identification of newNIBMs have revealed
that autoantibodies to TAA represent promising candidates
[12]. For example, it has been demonstrated that plasma
levels of IgG autoantibodies against heat shock protein 70 are
accurate to diagnose cholangiocarcinoma and that specificity
increases by adding autoantibodies to enolase-1 and ribonu-
clease/angiogenin inhibitor 1 [12]. Performing correlations
between the serum levels of a potential biomarker and
traditional markers of CLD pathologic events is a valid
strategy for the study of new NIBMs [31]. Therefore, to give
the first evidence about the potential of autoantibodies to
VEGFR-3 as NIBMs of BDL-induced liver injury, cholestasis,
and fibrosis, we performed correlations between absorbances
associatedwith the serum levels of autoantibodies toVEGFR-
3, obtained in the ELISA, and a panel of traditional markers
of liver injury (AST and ALT), cholestasis (TB), and fibrosis
(relative fibrotic area). AST and ALT are NIBMs that reflect
hepatic injury, providing valuable information regarding the
overall hepatic function [32]. The analysis of aminotrans-
ferase serum activity is commonly used as a first step in
the evaluation of patients with suspected CLD along with
the determination of other serum components. Bilirubin is
a marker of cholestasis [33]. A TB test is generally ordered to
help diagnoseCCLD, such as PSC andPBC.Moreover, hyper-
bilirubinemia, which characterizes severe CCLDs, has been
recognized as a major predictor of clinical outcomes in both
PBC and PSC [34, 35]. The relative fibrotic area, obtained by
computer-assisted image analysis of picrosirius red-stained
liver sections, is representative of the liver deposition of
collagen I and collagen III, two of the main components of
the extracellular matrix. Progressive accumulation of colla-
gen proteins occurs during liver fibrosis progression [36].
Therefore, the relative fibrotic area can be used to distinguish
the different stages of liver fibrosis [37]. In liver diseases,
excessive collagen deposition leads to structural disruption of
the normal liver architecture, liver stiffness, portal hyperten-
sion, and eventually hepatic failure [38–40]. In consequence,
methods to supervise the progression of fibrosis are crucial
to implement treatment strategies to prevent such events. In
this study, we showed that correlations between absorbances
relative to the serum levels of autoantibodies toVEGFR-3 and
AST, ALT, TB, and the relative fibrotic area were all signifi-
cant.These results prove that autoantibodies to VEGFR-3 are
correlated to BDL-induced liver injury, cholestasis, and fibro-
sis and support the need to further study these autoantibodies
in more types of animal models of liver injury, such as the
carbon tetrachloridemodel, as well as in human subjects with
CCLD. Interestingly, the correlation with TB was the highest
with 𝑅2 of 0.845. This finding, in parallel to the observation
that themean value of absorbances associated with the serum
levels of autoantibodies toVEGFR-3 is increased directly after
BDL and stays high without enabling the distinction between
one, three, and five weeks of BDL, a common tendency to
TB but not to the relative fibrotic area, suggests that levels
of autoantibodies to VEGFR-3 may be better associated with
cholestasis than fibrosis. This provides the first evidence on
the potential application of autoantibodies to VEGFR-3 as
NIBMs of cholestasis in CCLDs. To confirm that, further
studies on human patients with CCLD are needed.
5. Conclusion
This in vivo study demonstrated that BDL promotes the
production of VEGFR-3 specific autoantibodies that are early
measurable in the serum as soon as the first week after BDL-
induced chronic cholestatic liver injury. Although serum
levels of autoantibodies to VEGFR-3 significantly correlated
with markers of liver damage and fibrosis, the highest
correlation was with TB, suggesting that autoantibodies to
VEGFR-3 are closely related to BDL-induced cholestasis.
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